Brief: Prothena To Review Birtamimab Mechanism Of Action, Pharmacological Characteristics Published In Leukemia & Lymphoma
15/04/2024 23:09
April 15 (Reuters) - Prothena Corporation PLC PRTA.O :
* PROTHENA ANNOUNCES REVIEW ON BIRTAMIMAB MECHANISM OF
ACTION AND
PHARMACOLOGICAL CHARACTERISTICS PUBLISHED IN LEUKEMIA & LYMPHOMA
Source text for Eikon: ID:nBw10Qbtma
Further company coverage: PRTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment